These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 16187085)
1. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085 [TBL] [Abstract][Full Text] [Related]
2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
3. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239 [TBL] [Abstract][Full Text] [Related]
4. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053 [TBL] [Abstract][Full Text] [Related]
6. Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells. Nakai N; Asai J; Ueda E; Takenaka H; Katoh N; Kishimoto S J Dermatol; 2006 Jul; 33(7):462-72. PubMed ID: 16848818 [TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790 [TBL] [Abstract][Full Text] [Related]
8. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Belli F; Arienti F; Sulé-Suso J; Clemente C; Mascheroni L; Cattelan A; Santantonio C; Gallino GF; Melani C; Rao S; Colombo MP; Maio M; Cascinelli N; Parmiani G Cancer Immunol Immunother; 1997 Jun; 44(4):197-203. PubMed ID: 9222277 [TBL] [Abstract][Full Text] [Related]
9. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874 [TBL] [Abstract][Full Text] [Related]
10. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791 [TBL] [Abstract][Full Text] [Related]
11. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nestle FO; Alijagic S; Gilliet M; Sun Y; Grabbe S; Dummer R; Burg G; Schadendorf D Nat Med; 1998 Mar; 4(3):328-32. PubMed ID: 9500607 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF. Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM Front Immunol; 2020; 11():1147. PubMed ID: 32582212 [TBL] [Abstract][Full Text] [Related]